Fabrication of an antibody-aptamer sandwich assay for electrochemical evaluation of levels of β-amyloid oligomers

Zhou, Yanli; Zhang, Huanqing; Liu, Lantao; Li, Congming; Zhu, Chen; Zhu, Xu; Ye, Baoxian; Xu, Maotian

doi:10.1038/srep35186

Cited by 75 publications

(43 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22,23 Therefore, the direct detection of Aβ oligomer level would be more reliable for AD diagnosis than assay of its monomer. 24,25 Recently, a few novel biosensors have been developed for the detection of Aβ oligomer, including electrochemistry, [26][27][28][29] surface plasma resonance (SPR), 30 localized surface plasmon resonance (LSPR), 24,31 fluorescence, 32,33 nuclear magnetic resonance, 34 and surface-enhanced Raman spectroscopy. 35 These methods are feasible, but they require the use of special instruments and/or relatively expensive and variable antibodies for the capture and recognition of Aβ oligomer.…”

Section: Introductionmentioning

confidence: 99%

A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles

Xing¹,

Feng²,

Zhang³

et al. 2017

IJN

View full text Add to dashboard Cite

Soluble beta-amyloid (Aβ) oligomer is believed to be the most important toxic species in the brain of Alzheimer’s disease (AD) patients. Thus, it is critical to develop a simple method for the selective detection of Aβ oligomer with low cost and high sensitivity. In this paper, we report an electrochemical method for the detection of Aβ oligomer with a peptide as the bioreceptor and silver nanoparticle (AgNP) aggregates as the redox reporters. This strategy is based on the conversion of AgNP-based colorimetric assay into electrochemical analysis. Specifically, the peptide immobilized on the electrode surface and presented in solution triggered together the in situ formation of AgNP aggregates, which produced a well-defined electrochemical signal. However, the specific binding of Aβ oligomer to the immobilized peptide prevented the in situ assembly of AgNPs. As a result, a poor electrochemical signal was observed. The detection limit of the method was found to be 6 pM. Furthermore, the amenability of this method for the analysis of Aβ oligomer in serum and artificial cerebrospinal fluid (aCSF) samples was demonstrated.

show abstract

Section: Introductionmentioning

confidence: 99%

A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles

Xing¹,

Feng²,

Zhang³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…21 The detection limit for AβO detection of these electrochemical biosensors were from 0.5 to 500 pM. [17][18][19][20][21] In this study, a novel AβO biosensor made of graphene oxide (GO)/gold nanoparticles (GNPs) hydrogel was developed. Compared with traditional solid electrodes, soft graphene hydrogel electrodes have many advantages.…”

mentioning

confidence: 99%

A hydrogel biosensor for high selective and sensitive detection of amyloid-beta oligomers

Sun

Zhong

Gui

et al. 2018

IJN

View full text Add to dashboard Cite

Background Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive cognitive and memory impairment. It is the most common neurological disease that causes dementia. Soluble amyloid-beta oligomers (AβO) in blood or cerebrospinal fluid (CSF) are the pathogenic biomarker correlated with AD. Methods A simple electrochemical biosensor using graphene oxide/gold nanoparticles (GNPs) hydrogel electrode was developed in this study. Thiolated cellular prion protein (PrP C ) peptide probe was immobilized on GNPs of the hydrogel electrode to construct an AβO biosensor. Electrochemical impedance spectroscopy was utilized for AβO analysis. Results The specific binding between AβO and PrP C probes on the hydrogel electrode resulted in an increase in the electron-transfer resistance. The biosensor showed high specificity and sensitivity for AβO detection. It could selectively differentiate AβO from amyloid-beta (Aβ) monomers or fibrils. Meanwhile, it was highly sensitive to detect as low as 0.1 pM AβO in artificial CSF or blood plasma. The linear range for AβO detection is from 0.1 pM to 10 nM. Conclusion This biosensor could be used as a cost-effective tool for early diagnosis of AD due to its high electrochemical performance and bionic structure.

show abstract

“…AuNPs have also been used as labels for AD peptide biomarkers sensing [ 105 , 106 , 107 , 108 , 109 , 110 , 111 ]. Yoo et al [ 106 ] designed a sandwich-type immunosensor for the detection of Aβ peptide by using an antibody-modified interdigitated microelectrode and AuNPs conjugated with antibodies as labels for signal amplification ( Figure 7 A).…”

Section: Electrochemical Biosensors For Alzheimer’s Disease Diagnomentioning

confidence: 99%

“…Aptamer-antibody sandwich sensors have also been investigated in order to overcome the lack of sensitivity and transferability to commercial products of aptamer-based biosensors alone, exhibiting an improved sensitivity and specificity compared to the latter [ 131 ]. This is the case of Zhou et al [ 108 ] that used carboxyl graphene as electrode modifier for the immobilization of an antibody against Aβ oligomers using EDC/NHS chemistry and AuNPs functionalized with thionine as labels. The reduction process of thionine was electrochemically monitored for amplifying the signal recorded by DPV, providing a LOD of 100 pM.…”

Section: Electrochemical Biosensors For Alzheimer’s Disease Diagnomentioning

confidence: 99%

Electrochemical Biosensors Based on Nanomaterials for Early Detection of Alzheimer’s Disease

Toyos-Rodríguez

Alonso

Escosura‐Muñiz

2020

Sensors

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is an untreatable neurodegenerative disease that initially manifests as difficulty to remember recent events and gradually progresses to cognitive impairment. The incidence of AD is growing yearly as life expectancy increases, thus early detection is essential to ensure a better quality of life for diagnosed patients. To reach that purpose, electrochemical biosensing has emerged as a cost-effective alternative to traditional diagnostic techniques, due to its high sensitivity and selectivity. Of special relevance is the incorporation of nanomaterials in biosensors, as they contribute to enhance electron transfer while promoting the immobilization of biological recognition elements. Moreover, nanomaterials have also been employed as labels, due to their unique electroactive and electrocatalytic properties. The aim of this review is to add value in the advances achieved in the detection of AD biomarkers, the strategies followed for the incorporation of nanomaterials and its effect in biosensors performance.

show abstract

Fabrication of an antibody-aptamer sandwich assay for electrochemical evaluation of levels of β-amyloid oligomers

Cited by 75 publications

References 39 publications

A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles

A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles

A hydrogel biosensor for high selective and sensitive detection of amyloid-beta oligomers

Electrochemical Biosensors Based on Nanomaterials for Early Detection of Alzheimer’s Disease

Contact Info

Product

Resources

About